Gabapentin vs Pregabalin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: α2δ subunit of voltage-gated calcium channels · full Epilepsy pipeline
Gabapentin
Marketed by Viatris and partners
NCT00007670 · Phase 3 · completed
The study used randomization, double blinding, and an active carbamazepine control in a relatively large sample of 720 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms. (mixed)
Result source: NCT00007670
Pregabalin
Marketed by Viatris and partners
NCT01463306 · Phase 3 · completed
This was an open-label study with no randomization and no concurrent placebo or active-control arm, although it included 605 participants and some had continued from earlier studies. The primary outcomes were reported descriptively without a formal current-study comparison or statistical test, so the findings cannot establish comparative efficacy or safety.
Reported efficacy
Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) (missed)
Result source: NCT01747915
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gabapentin | Pregabalin |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00007670 | —Not posted · NCT00141245 |
| 50% responder rate | —Not posted · NCT00007670 | 40.6% vs 22.6%+18 vs placeboNCT013895963 other results
|
| Seizure freedom | —Not posted · NCT00007670 | —Not posted · NCT00141245 |
Seizure frequency, % change
- Gabapentin
- —Not posted · NCT00007670
- Pregabalin
- —Not posted · NCT00141245
50% responder rate
- Gabapentin
- —Not posted · NCT00007670
- Pregabalin
- 40.6% vs 22.6%+18 vs placeboNCT01389596
3 other results
- 53.6% vs 41.5% NCT02072824
- 30.5% vs 41.5% NCT02072824
- 29.1% vs 22.6% NCT01389596
Seizure freedom
- Gabapentin
- —Not posted · NCT00007670
- Pregabalin
- —Not posted · NCT00141245
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Gabapentin: 4 of 4 rows · Pregabalin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gabapentin | Pregabalin |
|---|---|---|
| Dropout rate | 10.1%a NCT00603473 · Phase 3 · monotherapy show 1 more result32.3% NCT00620555 · Phase 3 · registry result, not featured evidence | 45.5%Direct Pregabalinb NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 show 33 more results24.8%Placebo-Previous to Pregabalin-Cur NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 22.4%Pregabalin: Previous and Current NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 15.3%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day NCT01747915 · Phase 3 · monotherapy 20%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day NCT01747915 · Phase 3 · monotherapy 16.5%10 mg/kg/Day or 14 mg/kg/Day NCT01389596 · Phase 3 9.6%2.5 mg/kg/Day or 3.5 mg/kg/Day NCT01389596 · Phase 3 2.9%14 mg/kg/Day or 12 mg/kg/Day NCT02072824 · Phase 3 2.8%7 mg/kg/Day or 6 mg/kg/Day NCT02072824 · Phase 3 15.7% NCT00351611 · Phase 4 · registry result, not featured evidence 12.2% NCT00288639 · Phase 4 · registry result, not featured evidence 43.8%Pregabalin: 1-23 Months NCT00448916 · Phase 3 · registry result, not featured evidence 54.5%Pregabalin: 12-16 Years NCT00448916 · Phase 3 · registry result, not featured evidence 40%Pregabalin: 2-6 Years NCT00448916 · Phase 3 · registry result, not featured evidence 50%Pregabalin: 7-11 Years NCT00448916 · Phase 3 · registry result, not featured evidence 13.3%330 mg NCT01262677 · Phase 3 · registry result, not featured evidence 9%165 mg NCT01262677 · Phase 3 · registry result, not featured evidence 22.7% NCT00596466 · Phase 3 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 25%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 33.3%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 50%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 33.3%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.5%a NCT00603473 · Phase 3 · monotherapy show 1 more result6.2% NCT00620555 · Phase 3 · registry result, not featured evidence | 27.3%Direct Pregabalinb NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 show 33 more results4.3%Placebo-Previous to Pregabalin-Cur NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 1.6%Pregabalin: Previous and Current NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 6.9%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day NCT01747915 · Phase 3 · monotherapy 10.7%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day NCT01747915 · Phase 3 · monotherapy 4.1%10 mg/kg/Day or 14 mg/kg/Day NCT01389596 · Phase 3 1%2.5 mg/kg/Day or 3.5 mg/kg/Day NCT01389596 · Phase 3 0%14 mg/kg/Day or 12 mg/kg/Day NCT02072824 · Phase 3 0%7 mg/kg/Day or 6 mg/kg/Day NCT02072824 · Phase 3 12.4% NCT00351611 · Phase 4 · registry result, not featured evidence 5.1% NCT00288639 · Phase 4 · registry result, not featured evidence 12.5%Pregabalin: 1-23 Months NCT00448916 · Phase 3 · registry result, not featured evidence 18.2%Pregabalin: 12-16 Years NCT00448916 · Phase 3 · registry result, not featured evidence 13.3%Pregabalin: 2-6 Years NCT00448916 · Phase 3 · registry result, not featured evidence 25%Pregabalin: 7-11 Years NCT00448916 · Phase 3 · registry result, not featured evidence 7.1%330 mg NCT01262677 · Phase 3 · registry result, not featured evidence 3%165 mg NCT01262677 · Phase 3 · registry result, not featured evidence 5.3% NCT00596466 · Phase 3 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 25%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 33.3%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 50%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 33.3%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 1.1%a NCT00603473 · Phase 3 · monotherapy show 1 more result3.1% NCT00620555 · Phase 3 · registry result, not featured evidence | 9.1%Direct Pregabalinb NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 show 33 more results11%Placebo-Previous to Pregabalin-Cur NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 13.8%Pregabalin: Previous and Current NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 2.8%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day NCT01747915 · Phase 3 · monotherapy 2.7%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day NCT01747915 · Phase 3 · monotherapy 10.3%10 mg/kg/Day or 14 mg/kg/Day NCT01389596 · Phase 3 4.8%2.5 mg/kg/Day or 3.5 mg/kg/Day NCT01389596 · Phase 3 2.9%14 mg/kg/Day or 12 mg/kg/Day NCT02072824 · Phase 3 0%7 mg/kg/Day or 6 mg/kg/Day NCT02072824 · Phase 3 4.5% NCT00351611 · Phase 4 · registry result, not featured evidence — NCT00288639 · Phase 4 · registry result, not featured evidence 50%Pregabalin: 1-23 Months NCT00448916 · Phase 3 · registry result, not featured evidence 9.1%Pregabalin: 12-16 Years NCT00448916 · Phase 3 · registry result, not featured evidence 20%Pregabalin: 2-6 Years NCT00448916 · Phase 3 · registry result, not featured evidence 0%Pregabalin: 7-11 Years NCT00448916 · Phase 3 · registry result, not featured evidence 4.4%330 mg NCT01262677 · Phase 3 · registry result, not featured evidence 5%165 mg NCT01262677 · Phase 3 · registry result, not featured evidence 4.1% NCT00596466 · Phase 3 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%2.5 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 0%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence 33.3%15 mg/kg/Day NCT00437281 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultnasopharyngitis 43.1% somnolence 15.4% influenza 13.8% NCT00620555 · Phase 3 · registry result, not featured evidence | b headache 36.4% abdominal pain upper 18.2% increased appetite 18.2% NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 show 33 more resultsupper respiratory tract infection 14.3% somnolence 12.9% pyrexia 10.5% NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 upper respiratory tract infection 15.6% pyrexia 14.1% weight increased 7.3% NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day dizziness 16.7% (placebo 6.9%) headache 15.3% (placebo 16.7%) somnolence 15.3% (placebo 9.7%) NCT01747915 · Phase 3 · monotherapy 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day dizziness 17.3% (placebo 6.9%) headache 9.3% (placebo 16.7%) fatigue 6.7% (placebo 4.2%) NCT01747915 · Phase 3 · monotherapy 10 mg/kg/Day or 14 mg/kg/Day somnolence 25.8% (placebo 13.8%) weight increased 13.4% (placebo 4.3%) increased appetite 10.3% (placebo 4.3%) NCT01389596 · Phase 3 2.5 mg/kg/Day or 3.5 mg/kg/Day somnolence 17.3% (placebo 13.8%) upper respiratory tract infection 9.6% (placebo 9.6%) cough 8.7% (placebo 3.2%) NCT01389596 · Phase 3 14 mg/kg/Day or 12 mg/kg/Day somnolence 17.6% (placebo 5.7%) upper respiratory tract infection 11.8% (placebo 11.4%) nasopharyngitis 5.9% (placebo 4.3%) NCT02072824 · Phase 3 7 mg/kg/Day or 6 mg/kg/Day somnolence 11.3% (placebo 5.7%) upper respiratory tract infection 7% (placebo 11.4%) pyrexia 5.6% (placebo 5.7%) NCT02072824 · Phase 3 dizziness 22.5% (placebo 3.1%) somnolence 7.9% (placebo 3.1%) fatigue 6.7% (placebo 3.1%) NCT00351611 · Phase 4 · registry result, not featured evidence somnolence 20.4% dizziness 5.1% agitation 4.1% NCT00288639 · Phase 4 · registry result, not featured evidence pyrexia 56.3% constipation 31.3% cough 25% NCT00448916 · Phase 3 · registry result, not featured evidence pyrexia 27.3% excoriation 18.2% anger 9.1% NCT00448916 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 33.3% ear infection 26.7% otitis media 26.7% NCT00448916 · Phase 3 · registry result, not featured evidence convulsion 25% upper respiratory tract infection 16.7% aggression 8.3% NCT00448916 · Phase 3 · registry result, not featured evidence 330 mg dizziness 9.7% (placebo 1.8%) weight increased 6.2% (placebo 0%) fatigue 5.3% (placebo 0.9%) NCT01262677 · Phase 3 · registry result, not featured evidence 165 mg dizziness 11% (placebo 1.8%) fatigue 3% (placebo 0.9%) weight increased 1% (placebo 0%) NCT01262677 · Phase 3 · registry result, not featured evidence headache 5.5% nausea 5.5% arthralgia 4.1% NCT00596466 · Phase 3 · registry result, not featured evidence 10 mg/kg/Day electrocardiogram abnormal 33.3% (placebo 0%) vomiting 33.3% (placebo 0%) ataxia 0% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 10 mg/kg/Day dizziness 50% (placebo 0%) chest pain 25% (placebo 0%) fatigue 25% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 10 mg/kg/Day decreased appetite 33.3% (placebo 0%) dizziness 33.3% (placebo 0%) hypersomnia 33.3% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 10 mg/kg/Day lethargy 50% (placebo 0%) muscular weakness 50% (placebo 0%) psychomotor hyperactivity 50% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 5 mg/kg/Day somnolence 66.7% (placebo 50%) ataxia 33.3% (placebo 0%) balance disorder 0% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 5 mg/kg/Day irritability 33.3% (placebo 25%) pyrexia 33.3% (placebo 0%) sedation 33.3% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 5 mg/kg/Day dermatitis diaper 33.3% (placebo 0%) otitis media 33.3% (placebo 0%) pyrexia 33.3% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 5 mg/kg/Day seasonal allergy 33.3% (placebo 0%) sinus congestion 33.3% (placebo 0%) somnolence 33.3% (placebo 50%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 2.5 mg/kg/Day convulsion 33.3% (placebo 0%) ataxia 0% (placebo 0%) balance disorder 0% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 2.5 mg/kg/Day somnolence 33.3% (placebo 50%) ataxia 0% (placebo 0%) balance disorder 0% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 2.5 mg/kg/Day constipation 25% (placebo 0%) lethargy 25% (placebo 0%) somnolence 25% (placebo 50%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 2.5 mg/kg/Day somnolence 66.7% (placebo 50%) ataxia 0% (placebo 0%) balance disorder 0% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 15 mg/kg/Day somnolence 66.7% (placebo 50%) constipation 33.3% (placebo 0%) irritability 33.3% (placebo 25%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 15 mg/kg/Day balance disorder 50% (placebo 0%) dizziness 50% (placebo 0%) nausea 50% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 15 mg/kg/Day ataxia 33.3% (placebo 0%) constipation 33.3% (placebo 0%) drooling 33.3% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence 15 mg/kg/Day dizziness 66.7% (placebo 0%) dry mouth 33.3% (placebo 0%) headache 33.3% (placebo 0%) NCT00437281 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gabapentin
show 4 more results
show 4 more results
show 4 more results
Pregabalin
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 6 more results
show 3 more results
+ 10 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gabapentin's landscape · Pregabalin's landscape